- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03808038
Symptoms of Lower Urinary Tract Dysfunction Protocol 2/Recall Study
Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Protocol 2/Recall Study
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This protocol is part of an overall effort to create a state-of-the-art resource for measuring patient-reported health for patients with lower urinary tract dysfunction (LUTD). The primary purpose of this resource, known as the LURN PRO Battery, is to comprehensively characterize the self-reported experiences of patients with LUTD for the purpose of enhancing efforts to characterize and explain important subtypes of patients with LUTD (phenotypes). Secondary purposes of the LURN PRO Battery, for which additional development work will be required, include developing better patient-reported endpoints for clinical trials, monitoring symptoms in the course of clinical care, and screening patients into important subgroups for purposes of tailored interventions.
Incorporating methods the investigators have used successfully in prior measure validation work, the investigators propose to conduct a diary study in which patients record their symptoms at various time points - at the end of each day, or across multiple days. The investigators also ask them to complete self-report measures with different recall periods (i.e., 3-day, 7-day, and 30-day recall), and will determine how well each of these correspond to daily experiences recorded in more frequent assessments (i.e., end-of-day and 3-day patient bladder diaries). These data will help LURN investigators to determine the most appropriate reporting period for specific symptoms. This study can also help to identify causes of differences that exist between shorter and longer recall periods.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Northwestern University
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- University of Iowa
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- University of Michigan
-
-
Missouri
-
Saint Louis, Missouri, États-Unis, 63110
- Washington University
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27715
- Duke University
-
-
Washington
-
Seattle, Washington, États-Unis, 98195
- University of Washington
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- age 18 or older,
- willing and able to give informed consent,
- able to speak, read, and understand English,
- able to reliably complete self-reported questionnaires online at specified times (i.e., may exclude those who do not keep a regular schedule of sleeping during night hours), and
- experienced at least moderate severity and bother from at least 1 of the 7 targeted symptoms in the past 2 weeks and in the past 3 months
Exclusion Criteria:
- dementia or other cognitive impairment that would interfere with study participation,
- known pregnancy or delivery within past 6 months (women only)
- planned change in medications to treat LUTS in the middle of the study time frame,
- receiving active treatment for any malignancy (including maintenance medications),
- received surgery with general or spinal/epidural anesthesia in the past 3 months or planned surgery during the study time frame
- lower urinary tract instrumentation (e.g. self-catheterization or cystoscopy) in past 3 months or planned during the study time frame and
- prostate biopsy in the past 3 months or planned during the study time frame
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
No Diary Group
Group completed daily questionnaires for four weeks, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
|
None- Observational Study
|
|
Diary Start Group
Group completed bladder diaries in week 1, daily questionnaires in week 1, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
|
None- Observational Study
|
|
Daily Start Group
Group completed daily questionnaires in week 1, bladder diaries in week 2, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
|
None- Observational Study
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Determine ideal recall period for LUTS symptoms
Délai: Through study completion - 30 days
|
The investigators will administer and analyze the correspondence between patient's average daily recall of their LUTS utilizing seven, daily questionnaires, their weekly recall of self-reported LUTS using a 7-day recall questionnaire, as well as a questionnaire assessing their monthly LUTS recall in order to determine the best recall period to utilize when administering LUTS questionnaires in clinical settings.
|
Through study completion - 30 days
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Kevin P. Weinfurt, PhD, Duke University
- Chaise d'étude: Claire C. Yang, MD, University of Washington
- Chercheur principal: Robert M. Merion, MD, FACS, Arbor Research Collaborative for Health - DCC
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- LURN Recall Study
- U01DK100017 (Subvention/contrat des NIH des États-Unis)
- U01DK100011 (Subvention/contrat des NIH des États-Unis)
- U01DK099932 (Subvention/contrat des NIH des États-Unis)
- U01DK099879 (Subvention/contrat des NIH des États-Unis)
- U01DK097780 (Subvention/contrat des NIH des États-Unis)
- U01DK097779 (Subvention/contrat des NIH des États-Unis)
- U01DK097776 (Subvention/contrat des NIH des États-Unis)
- U01DK097772 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur None- Observational Study
-
Apple Inc.Stanford UniversityComplétéFibrillation auriculaire | Arythmies cardiaques | Flutter auriculaireÉtats-Unis
-
Radicle ScienceComplétéLa dépression | La douleur | Dormir | AnxiétéÉtats-Unis
-
Radboud University Medical CenterUCB Pharma; Verily Life Sciences LLCActif, ne recrute pasMaladies du cerveau | Maladies du système nerveux central | Maladies du système nerveux | Maladie de Parkinson | Troubles parkinsoniens | Maladies des noyaux gris centraux | Troubles du mouvement | Maladies neurodégénérativesPays-Bas
-
Radboud University Medical CenterUCB Pharma; Verily Life Sciences LLCComplétéMaladies du cerveau | Troubles du mouvement | Maladies neurodégénératives | Paralysie supranucléaire progressivePays-Bas
-
Radicle ScienceComplété
-
Radicle ScienceComplété
-
Radicle ScienceComplété
-
Digisight Technologies, Inc.InconnueLa rétinopathie diabétique | Dégénérescence maculaire liée à l'âge | MétamorphopsieÉtats-Unis
-
Radicle ScienceComplétéFonction sexuelle | Satisfaction sexuelleÉtats-Unis
-
St. Joseph's Healthcare HamiltonSuspendu